Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
The effectiveness of a vaccine is determined not only by the immunogenicity of its components, but especially by how widely it covers the disease-causing strains circulating in a given region. Because vaccine coverage varies over time, this study aimed to detect possible changes that could affect va...
Main Authors: | Emilio Pérez-Trallero, Olatz Esnal, José M Marimón |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4277446?pdf=render |
Similar Items
-
Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France
by: Eva Hong, et al.
Published: (2021-12-01) -
Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
by: Susanna Esposito, et al.
Published: (2015-01-01) -
Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
by: Véronique Abitbol, et al.
Published: (2023-08-01) -
Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
by: Margherita Bodini, et al.
Published: (2020-10-01) -
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
by: Yara Ruiz García, et al.
Published: (2021-10-01)